HC Wainwright Has Bullish Forecast for ACAD FY2027 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at HC Wainwright upped their FY2027 EPS estimates for ACADIA Pharmaceuticals in a research report issued on Thursday, May 8th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $2.06 for the year, up from their prior forecast of $2.05. HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.19 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.10 by $0.01. The firm had revenue of $244.32 million for the quarter, compared to analysts' expectations of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company's revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 EPS.

A number of other equities research analysts have also recently issued reports on ACAD. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley restated an "equal weight" rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, March 8th. Finally, UBS Group lowered their price target on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.70.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $17.44 on Monday. The stock's 50-day simple moving average is $15.83 and its 200 day simple moving average is $16.98. The company has a market cap of $2.92 billion, a P/E ratio of 22.36 and a beta of 0.47. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $20.68.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ACAD. Barclays PLC raised its position in shares of ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after buying an additional 154,854 shares in the last quarter. Burney Co. acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $6,953,000. Hennion & Walsh Asset Management Inc. raised its holdings in ACADIA Pharmaceuticals by 7.8% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 103,325 shares of the biopharmaceutical company's stock valued at $1,896,000 after acquiring an additional 7,491 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after acquiring an additional 1,966,607 shares during the period. Finally, KBC Group NV grew its holdings in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 2,044 shares in the last quarter. Institutional investors own 96.71% of the company's stock.

Insider Transactions at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. The trade was a 21.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,498 shares of the firm's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $14.60, for a total transaction of $51,070.80. Following the transaction, the executive vice president now directly owns 62,773 shares in the company, valued at approximately $916,485.80. This represents a 5.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,994 shares of company stock worth $313,131. Company insiders own 26.50% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.